HURA logo

TuHURA Biosciences, Inc.

HURA
Healthcare|Biotechnology|US
$1.63
+0.02 (+1.24%)
Tangible Book / Share
$0.12
Cash / Share
$0.02
Next Earnings Report
Nov 13, 2026
EPS est. -$0.14
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Apr 8, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Mar 2027
Est. completion
P2P3Advanced Or Metastatic Merkel Cell Carcinoma
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928n=118
Apr 2027
Est. completion
P1Advanced Or Metastatic Merkel Cell Carcinoma
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NCT06940440n=9

Recent Press Releases

TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026 · PRNewsWire
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
Oct 26, 2026 · PRNewsWire
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Oct 13, 2026 · PRNewsWire
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
Oct 5, 2026 · PRNewsWire
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
Sep 14, 2026 · PRNewsWire
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · PRNewsWire
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Aug 14, 2026 · PRNewsWire

SEC Filings (97)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 20268-KMaterial eventDocumentIndex
Oct 16, 20268-KMaterial eventDocumentIndex
Sep 24, 20268-KMaterial eventDocumentIndex
Sep 17, 20268-KMaterial eventDocumentIndex
Sep 17, 20268-K/AMaterial eventDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Sep 4, 20268-KMaterial eventDocumentIndex
Aug 28, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 21, 20268-KMaterial eventDocumentIndex
Aug 19, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
Jul 9, 2026ARSAnnual report to holdersDocumentIndex
Jul 9, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 9, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jul 7, 20268-KMaterial eventDocumentIndex
Jun 26, 2026PRE 14AProxy / shareholder voteDocumentIndex
Jun 17, 20268-KMaterial eventDocumentIndex
May 29, 20268-KMaterial eventDocumentIndex
May 15, 202610-QQuarterly reportDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
Apr 30, 20268-K/AMaterial eventDocumentIndex
Apr 30, 202610-K/AAnnual reportDocumentIndex
Apr 22, 20268-KMaterial eventDocumentIndex
Apr 8, 2026424B5Offering prospectusDocumentIndex
Apr 8, 20268-KMaterial eventDocumentIndex
Apr 1, 20268-KMaterial eventDocumentIndex
Mar 31, 202610-KAnnual reportDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Dec 10, 20258-KMaterial eventDocumentIndex
Dec 10, 2025424B5Offering prospectusDocumentIndex
Dec 5, 20258-KMaterial eventDocumentIndex
Nov 25, 20258-KMaterial eventDocumentIndex
Nov 25, 2025424B3Offering prospectusDocumentIndex
Nov 18, 20258-KMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Nov 14, 20258-KMaterial eventDocumentIndex